Cargando…

Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy

PURPOSE: Although stereotactic ablative body radiotherapy (SABR) is widely used therapeutic technique, predictive factors of radiation pneumonitis (RP) after SABR remain undefined. We aimed to investigate the predictive factors affecting RP in patients with primary or metastatic lung tumors who rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kangpyo, Lee, Jeongshim, Cho, Yeona, Chung, Seung Yeun, Lee, Jason Joon Bock, Lee, Chang Geol, Cho, Jaeho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Radiation Oncology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518451/
https://www.ncbi.nlm.nih.gov/pubmed/28712275
http://dx.doi.org/10.3857/roj.2017.00066
_version_ 1783251496320630784
author Kim, Kangpyo
Lee, Jeongshim
Cho, Yeona
Chung, Seung Yeun
Lee, Jason Joon Bock
Lee, Chang Geol
Cho, Jaeho
author_facet Kim, Kangpyo
Lee, Jeongshim
Cho, Yeona
Chung, Seung Yeun
Lee, Jason Joon Bock
Lee, Chang Geol
Cho, Jaeho
author_sort Kim, Kangpyo
collection PubMed
description PURPOSE: Although stereotactic ablative body radiotherapy (SABR) is widely used therapeutic technique, predictive factors of radiation pneumonitis (RP) after SABR remain undefined. We aimed to investigate the predictive factors affecting RP in patients with primary or metastatic lung tumors who received SABR. MATERIALS AND METHODS: From 2012 to 2015, we reviewed 59 patients with 72 primary or metastatic lung tumors treated with SABR, and performed analyses of clinical and dosimetric variables related to symptomatic RP. SABR was delivered as 45–60 Gy in 3–4 fractions, which were over 100 Gy in BED when the α/β value was assumed to be 10. Tumor volume and other various dose volume factors were analyzed using median value as a cutoff value. RP was graded per the Common Terminology Criteria for Adverse Events v4.03. RESULTS: At the median follow-up period of 11 months, symptomatic RP was observed in 13 lesions (12 patients, 18.1%), including grade 2 RP in 11 lesions and grade 3 in 2 lesions. Patients with planning target volume (PTV) of ≤14.35 mL had significantly lower rates of symptomatic RP when compared to others (8.6% vs. 27%; p = 0.048). Rates of symptomatic RP in patients with internal gross tumor volume (iGTV) >4.21 mL were higher than with ≤4.21 mL (29.7% vs. 6.1%; p = 0.017). CONCLUSIONS: The incidence of symptomatic RP following treatment with SABR was acceptable with grade 2 RP being observed in most patients. iGTV over 4.21 mL and PTV of over 14.35 mL were significant predictive factors related to symptomatic RP.
format Online
Article
Text
id pubmed-5518451
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Society for Radiation Oncology
record_format MEDLINE/PubMed
spelling pubmed-55184512017-07-20 Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy Kim, Kangpyo Lee, Jeongshim Cho, Yeona Chung, Seung Yeun Lee, Jason Joon Bock Lee, Chang Geol Cho, Jaeho Radiat Oncol J Original Article PURPOSE: Although stereotactic ablative body radiotherapy (SABR) is widely used therapeutic technique, predictive factors of radiation pneumonitis (RP) after SABR remain undefined. We aimed to investigate the predictive factors affecting RP in patients with primary or metastatic lung tumors who received SABR. MATERIALS AND METHODS: From 2012 to 2015, we reviewed 59 patients with 72 primary or metastatic lung tumors treated with SABR, and performed analyses of clinical and dosimetric variables related to symptomatic RP. SABR was delivered as 45–60 Gy in 3–4 fractions, which were over 100 Gy in BED when the α/β value was assumed to be 10. Tumor volume and other various dose volume factors were analyzed using median value as a cutoff value. RP was graded per the Common Terminology Criteria for Adverse Events v4.03. RESULTS: At the median follow-up period of 11 months, symptomatic RP was observed in 13 lesions (12 patients, 18.1%), including grade 2 RP in 11 lesions and grade 3 in 2 lesions. Patients with planning target volume (PTV) of ≤14.35 mL had significantly lower rates of symptomatic RP when compared to others (8.6% vs. 27%; p = 0.048). Rates of symptomatic RP in patients with internal gross tumor volume (iGTV) >4.21 mL were higher than with ≤4.21 mL (29.7% vs. 6.1%; p = 0.017). CONCLUSIONS: The incidence of symptomatic RP following treatment with SABR was acceptable with grade 2 RP being observed in most patients. iGTV over 4.21 mL and PTV of over 14.35 mL were significant predictive factors related to symptomatic RP. The Korean Society for Radiation Oncology 2017-06 2017-06-30 /pmc/articles/PMC5518451/ /pubmed/28712275 http://dx.doi.org/10.3857/roj.2017.00066 Text en Copyright © 2017. The Korean Society for Radiation Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Kangpyo
Lee, Jeongshim
Cho, Yeona
Chung, Seung Yeun
Lee, Jason Joon Bock
Lee, Chang Geol
Cho, Jaeho
Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy
title Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy
title_full Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy
title_fullStr Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy
title_full_unstemmed Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy
title_short Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy
title_sort predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518451/
https://www.ncbi.nlm.nih.gov/pubmed/28712275
http://dx.doi.org/10.3857/roj.2017.00066
work_keys_str_mv AT kimkangpyo predictivefactorsofsymptomaticradiationpneumonitisinprimaryandmetastaticlungtumorstreatedwithstereotacticablativebodyradiotherapy
AT leejeongshim predictivefactorsofsymptomaticradiationpneumonitisinprimaryandmetastaticlungtumorstreatedwithstereotacticablativebodyradiotherapy
AT choyeona predictivefactorsofsymptomaticradiationpneumonitisinprimaryandmetastaticlungtumorstreatedwithstereotacticablativebodyradiotherapy
AT chungseungyeun predictivefactorsofsymptomaticradiationpneumonitisinprimaryandmetastaticlungtumorstreatedwithstereotacticablativebodyradiotherapy
AT leejasonjoonbock predictivefactorsofsymptomaticradiationpneumonitisinprimaryandmetastaticlungtumorstreatedwithstereotacticablativebodyradiotherapy
AT leechanggeol predictivefactorsofsymptomaticradiationpneumonitisinprimaryandmetastaticlungtumorstreatedwithstereotacticablativebodyradiotherapy
AT chojaeho predictivefactorsofsymptomaticradiationpneumonitisinprimaryandmetastaticlungtumorstreatedwithstereotacticablativebodyradiotherapy